Secondly, the identification of iron-related genetic variants may be used to select post-DAA patients with persistent iron overload and advanced fibrosis or cirrhosis who may benefit from adjuvant interventions such as therapeutic phlebotomy, hepcidin agonists or modulators, antioxidant therapies, or dietary strategies to limit iron intake. This evidence concerns the gene HAMP and Cirrhosis.